A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
Public ClinicalTrials.gov record NCT01178125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of a Combination Oral Contraceptive Regimen (DR-102) for the Prevention of Pregnancy in Women
Study identification
- NCT ID
- NCT01178125
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Enrollment
- 2,858 participants
Conditions and interventions
Conditions
Interventions
- DR-102 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 40 Years
- Sex
- Female
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2010
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
- Last update posted
- Nov 8, 2021
2010 – 2013
United States locations
- U.S. sites
- 52
- U.S. states
- 21
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Teva Investigational Site 10007 | Montgomery | Alabama | — | — |
| Teva Investigational Site 10013 | Phoenix | Arizona | — | — |
| Teva Investigational Site 10017 | Phoenix | Arizona | — | — |
| Teva Investigational Site 10032 | Little Rock | Arkansas | — | — |
| Teva Investigational Site 10026 | San Diego | California | — | — |
| Teva Investigational Site 10056 | San Diego | California | — | — |
| Teva Investigational Site 10002 | Colorado Springs | Colorado | — | — |
| Teva Investigational Site 10033 | Colorado Springs | Colorado | — | — |
| Teva Investigational Site 10057 | Washington D.C. | District of Columbia | — | — |
| Teva Investigational Site 10052 | Clearwater | Florida | — | — |
| Teva Investigational Site 10021 | Jacksonville | Florida | — | — |
| Teva Investigational Site 10036 | Leesburg | Florida | — | — |
| Teva Investigational Site 10012 | Miami | Florida | — | — |
| Teva Investigational Site 10015 | Miami | Florida | — | — |
| Teva Investigational Site 10055 | Palm Beach Gardens | Florida | — | — |
| Teva Investigational Site 10001 | West Palm Beach | Florida | — | — |
| Teva Investigational Site 10031 | Decatur | Georgia | — | — |
| Teva Investigational Site 10041 | Roswell | Georgia | — | — |
| Teva Investigational Site 10050 | Savannah | Georgia | — | — |
| Teva Investigational Site 10008 | Louisville | Kentucky | — | — |
| Teva Investigational Site 10023 | Mount Sterling | Kentucky | — | — |
| Teva Investigational Site 10048 | Lawrenceville | New Jersey | — | — |
| Teva Investigational Site 10030 | Moorestown | New Jersey | — | — |
| Teva Investigational Site 10014 | Albuquerque | New Mexico | — | — |
| Teva Investigational Site 10006 | Rochester | New York | — | — |
| Teva Investigational Site 10044 | Cary | North Carolina | — | — |
| Teva Investigational Site 10040 | Charlotte | North Carolina | — | — |
| Teva Investigational Site 10034 | New Bern | North Carolina | — | — |
| Teva Investigational Site 10018 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 10046 | Winston-Salem | North Carolina | — | — |
| Teva Investigational Site 10022 | Columbus | Ohio | — | — |
| Teva Investigational Site 10039 | Columbus | Ohio | — | — |
| Teva Investigational Site 10028 | Oklahoma City | Oklahoma | — | — |
| Teva Investigational Site 10043 | Philadelphia | Pennsylvania | — | — |
| Teva Investigational Site 10003 | Pittsburgh | Pennsylvania | — | — |
| Teva Investigational Site 10049 | Bluffton | South Carolina | — | — |
| Teva Investigational Site 10037 | Columbia | South Carolina | — | — |
| Teva Investigational Site 10035 | Greenville | South Carolina | — | — |
| Teva Investigational Site 10047 | Mt. Pleasant | South Carolina | — | — |
| Teva Investigational Site 10016 | Jackson | Tennessee | — | — |
| Teva Investigational Site 10045 | Knoxville | Tennessee | — | — |
| Teva Investigational Site 10005 | Memphis | Tennessee | — | — |
| Teva Investigational Site 10042 | Nashville | Tennessee | — | — |
| Teva Investigational Site 10054 | Dallas | Texas | — | — |
| Teva Investigational Site 10019 | Houston | Texas | — | — |
| Teva Investigational Site 10020 | San Antonio | Texas | — | — |
| Teva Investigational Site 10038 | Arlington | Virginia | — | — |
| Teva Investigational Site 10024 | Norfolk | Virginia | — | — |
| Teva Investigational Site 10051 | Norfolk | Virginia | — | — |
| Teva Investigational Site 10053 | Richmond | Virginia | — | — |
| Teva Investigational Site 10027 | Seattle | Washington | — | — |
| Teva Investigational Site 10029 | Tacoma | Washington | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01178125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 8, 2021 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01178125 live on ClinicalTrials.gov.